AdaptHealth Corp - 1782060 - ADAPTHEALTH CORP

Financial Performance:

• Exited Q3 2026 with Kaiser Permanente margins turning from negative to a 14% run rate, driven by reduced urgent orders and improved labor/OPEX efficiency; target of 20% margin by late 2027 remains in active renegotiation to right-size the contract.
• Underlying base business achieved 4% organic year-over-year growth in the current period, constrained by the requirement to maintain diabetes segment operations pending sale.
• Debt levels currently stand at approximately 3.0x leverage; management targets a return to 2.5x leverage utilizing diabetes divestiture proceeds and free cash flow, with buybacks and opportunistic M&A on the table once the target is reached.
• Approximately $30 million in allocated costs will be eliminated immediately, with an additional $30 million in stranded costs expected to be absorbed via organic growth over the next two years.
• ResMed rebate structure and pricing tiers were restored to normal course of business by the end of the quarter following a temporary disruption.

Guidance and Future Outlook:

• Full-year outlook emphasizes stabilizing the Kaiser contract and leveraging the West Coast infrastructure for non-Kaiser growth in H2 2027 (the "halo effect").
• 2027 strategy focuses on "blocking and tackling," organic growth in sleep and respiratory segments, and operational standardization without transformative M&A.
• West Coast expansion is a top priority for 2027, leveraging existing 40 locations and capital investments to capture non-Kaiser market share in California.
• Management expects the diabetes sale to close in the first half of 2027, releasing capital to fund base business reinvestment.
• No major capital expenditure spikes anticipated; CapEx expected to normalize as a percentage of revenue following the inventory and technology build-out phase.

Business Segments and Product Lines:

• Sleep & Respiratory: Core focus for growth, utilizing capitated agreements and enterprise sales initiatives to secure large health systems and managed care partners; margins on non-Kaiser capitation deals are at or above enterprise average.
• Wellness at Home: Supports core segments with supply chain and logistics capabilities; expanding via drop-shipping and standardized workflows.
• Diabetes: Divestment to Cardinal Health is on track for H1 2027; no new investments or cost reductions will occur in this segment until the transaction closes.
• Digital & Tech: "MyApp" currently has 615,000 users with a goal of 2 million by 2028; AI mask fitting tools achieve a 94% order conversion rate; Oracle, Brightree, Snap, and Snowflake infrastructure is fully matured.
• New Agreements: Recent wins include 70,000+ lives with two new regional capitated contracts (similar to Humana footprint expansion) and ongoing preferred provider agreements with large health systems.

Market and Competitive Landscape:

• Adapt Health is positioning itself as the only national player with significant West Coast scale, differentiating from regional competitors through advanced tech infrastructure and mature operations.
• Industry consolidation favors larger players with purchasing power and established technology backends; payers are actively seeking to consolidate networks into single providers.
• Competitors face challenges in billing sophistication and disaster recovery planning, where Adapt's mature tech stack provides a competitive moat.
• Potential new market entrants in the sleep space could increase leverage for Adapt in supplier negotiations, though current focus remains on securing inventory for branded prescriptions.
• The Medline field action regarding beds has been mitigated via front-of-line supply agreements; cost impact is minimal (~7-8% of revenue) and baked into low-end guidance.

Risks and Challenges:

• Kaiser Permanente Contract: Significant initial utilization data discrepancies and pent-up demand caused margin volatility; current focus is on renegotiating the "jump-off" point and baseline data.
• Regulatory: Medicare billing number moratorium on the West Coast delayed non-Kaiser growth but was used to operationalize the region; lifting of the moratorium in H2 2027 enables full market expansion.
• Supply Chain: Reliance on specific manufacturers (ResMed, Medline) requires continuous monitoring of pricing, rebates, and field actions (e.g., Medline bed recalls).
• Operational Integration: Standardizing operations across acquired assets continues to be a work-in-progress, though 2 years of discipline have yielded significant OPEX reductions.
• Stranded Costs: $30 million in costs not directly tied to the diabetes segment must be managed via organic growth rather than immediate elimination.

Management Commentary and Tone:

• Management tone is confident and forward-looking, characterizing 2026 as a "transformational" year that has cleared the path for a "calming" 2027.
• CEO Suzanne Foster emphasized that the company has moved past "kindergarten" operations to "middle school" maturity, citing standardized work, tech infrastructure, and commercial strategy as key drivers.
• CFO Harris highlighted strong balance sheet management, noting the redemption of high-cost senior notes and a disciplined approach to deleveraging.
• The team expressed frustration with the unpredictability of the initial Kaiser data but asserted that the contract is now stable and a "leverageable asset" for West Coast expansion.

Analyst Questions and Answers:

• Q: Timeline for Kaiser contract resolution? A: Goal is finalization by end of calendar year to ensure budgeting certainty for 2027.
• Q: Can Kaiser infrastructure be leveraged for other West Coast business? A: Yes, pending Medicare billing number approval in H2 2027, non-Kaiser business will be acquired without incremental CapEx ("halo effect").
• Q: How does the diabetes sale impact costs and leverage? A: $30M of allocated costs eliminated immediately; remaining $30M stranded costs absorbed by 2028 growth; leverage will settle at ~3.0x post-sale before trending toward 2.5x.
• Q: Status of ResMed negotiations? A: Rebate structures and pricing tiers restored to normal course; negotiations for the following year are underway.
• Q: Impact of new sleep market entrants? A: Additional players increase Adapt's supplier leverage; company is preparing to manage inventory for diverse supplier brands.
• Q: Details on Medline field action impact? A: Costs are minimal; supply chain secured; potential for upside if shortages arise.

Other Key Points:

• The company has successfully transitioned from a "roll-up consolidator" of 150 HME companies to a focused sleep, respiratory, and wellness-at-home business.
• Administrative burden is reduced due to mature tech stack (Oracle, Snowflake, etc.), contrasting with peers still incurring heavy IT investment costs.
• Strategic focus has shifted from geographic expansion via M&A to organic growth via capitated agreements and enterprise sales initiatives.
• Management reaffirmed that the company is not a consolidator of brick-and-mortar assets but is open to acquiring "patient care" (resupply) businesses.